drugset / Trial / NCT06085482
A Phase I Study of LY3502970 in Healthy Participants
NaSingle-groupOpen-labelBasic science
Summary
The main purpose of this study is to evaluate how much of the study drug (LY3502970) and the radioactive substance 14C incorporated LY3502970 gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 9 weeks for each participant.
Timeline
- Start
- 2023-10-19
- Primary completion
- 2024-01-05
- Completion
- 2024-01-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orforglipron | Small molecule | 21 ug | Oral |
| Subject | Orforglipron | Small molecule | 1 mg | Oral |
Indications
No indication recorded.